ABSTRACT
Introduction Point-of-care (POC) quantification of the antibody responses against the SARS-CoV-2 Spike protein can enable decentralized monitoring of immune responses after infection or vaccination. We evaluated a novel POC microfluidic cartridge-based device (ViroTrack Sero COVID-19 Total Ab) for quantitative detection of total antibodies against SARS-CoV-2 Spike trimeric spike protein and compared to standard laboratory chemiluminescence (CLIA) based tests.
Methods Capillary- and venous blood samples were collected from 101 individuals employed at Copenhagen University Hospital, Denmark. Antibody responses were measured on capillary-, venous whole blood, plasma and diluted plasma samples directly on the POC instrument. POC results were available within seven minutes on the microfluidic cartridge reader. Plasma samples were analysed on the DiaSorin LIAISON® XL CLIA Analyzer using LIAISON® SARS-CoV-2 IgM, LIAISON® SARS-CoV-2 S1/S2 IgG and LIAISON® SARS-CoV-2 TrimericS IgG assays. The data from the CLIA platform was used as a reference.
Results The Spearman rank’s correlation coefficient between ViroTrack Sero COVID-19 Total Ab and LIAISON® SARS-CoV-2 S1/S2 IgG and LIAISON® SARS-CoV-2 TrimericS IgG assays is found to be 0.86 and 0.90 respectively. ViroTrack Sero COVID-19 Total Ab furthermore showed high correlation (>0.86) among the different sample matrixes. The agreement for determination of samples >200 BAU/mL on POC and CLIA methods is estimated to be around 90%.
Conclusion ViroTrack Sero Covid Total Ab is a very rapid and simple-to-use POC test with high sensitivity and high correlation of the numerical results expressed in BAU/mL when compared to a commercial CLIA assay.
Competing Interest Statement
1 P. Pah, M. Bade, J. Fock, S. and M. Donolato are employed at Blusense Diagnostics APS and have been part of the developing of ViroTrack Sero COVID-19 Total Ab. 2 This work was supported by BluSense Diagnostics in forms of providing the test kits for the study.
Funding Statement
NA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Regional Ethics Committee of the Capital Region of Denmark (record no. H-20046624). The study was further approved by the Regional Data Protection Center (record no. P-2020-358).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclaimers:
Data Availability
Data available upon request
